Cardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma
Cancer Science · 17.11.2026
DOI: 10.1111/cas.70596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 17.11.2026. Verfasst von Tomoyuki Nakamura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Although immunotherapies have improved outcomes in multiple myeloma (MM), therapeutic resistance remains a major challenge, thereby underscoring the need for strategies that enhance tumor immunogenicity. Here, we show that cardiac glycosides (CGs), including periplocin and digoxin, act as immunogenic sensitizers in MM. CG treatment upregulated the cell‐surface expression of ICAM‐1, 4‐1BBL, and SLAMF7 in MM cell lines and primary patient‐derived CD138 + cells. Mechanistically, our findings support the involvement of Na + /K + ‐ATPase inhibition, Ca 2+ signaling, and mitochondrial‐ and endoplasmic reticulum (ER)‐associated ROS pathways in CG‐induced immune remodeling. CGs also induced immunogenic cell death (ICD)‐associated changes, including cell‐surface calreticulin exposure and extracellular HMGB1 and ATP release. These changes were associated with ferroptosis, as indicated by intracellular Fe 2+ accumulation, lipid peroxidation, elevated malondialdehyde levels, and attenuation of ICD markers by ferroptosis inhibitors. Functionally, CG treatment enhanced the cytotoxic effects of elotuzumab and teclistamab by promoting effector T‐ and NK‐cell‐mediated killing. Collectively, our findings suggest that the Na + /K + ‐ATPase–Ca 2+ –ROS axis contributes to immune remodeling and ferroptosis‐associated ICD in MM. These results provide mechanistic insights into stress‐induced tumor immunogenicity and support further investigation of CGs as sensitizers for antibody‐based immunotherapy in MM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Cell Signaling, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
ORCID-Profile: Tomoyuki Nakamura, Masaki Ri, Toru Ebina, Hirokazu Sasaki, Shinsuke Iida
Zitieren
APA
Nakamura, T., Ri, M., Ebina, T., Marumo, Y., Sasaki, H., Oshima, Y., Kato, C., Nakashima, T., Kinoshita, S., Suzuki, T., Sanda, T., Komatsu, H., Inoue, Y., Hayashi, H., & Iida, S. (2026). Cardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma. Cancer Science. https://doi.org/10.1111/cas.70596
Vancouver
Nakamura T, Ri M, Ebina T, Marumo Y, Sasaki H, Oshima Y, et al. Cardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma. Cancer Science. 2026. doi:10.1111/cas.70596
BibTeX
@article{Nakamura2026,
author = {Nakamura, Tomoyuki and Ri, Masaki and Ebina, Toru and Marumo, Yoshiaki and Sasaki, Hirokazu and Oshima, Yoshiko and Kato, Chie and Nakashima, Takahiro and Kinoshita, Shiori and Suzuki, Tomotaka and Sanda, Takaomi and Komatsu, Hirokazu and Inoue, Yasumichi and Hayashi, Hidetoshi and Iida, Shinsuke},
title = {Cardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70596}
}
EUVIMED